SCHEMBL31161355

SCHEMBL31161355

CC(C)(C)OC(=O)N1CC=C(N2CC(CN3CCN(C(=O)c4ccc(Cl)c(N5CCC(=O)NC5=O)c4)CC3)C2)C(F)(F)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.35
▸ CRBN Q96SW2 8/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ DDB1 Q16531 7/20 0.33
▸ PDK1 Q15118 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ PDK3 Q15120 1/20 0.33
▸ PDK4 Q16654 1/20 0.33
▸ SOS1 Q07889 1/20 0.32
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ NR3C1 P04150 1/20 0.31
▸ PGR P06401 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ PDE3B Q13370 1/20 0.31
▸ PDE3A Q14432 1/20 0.31
▸ TNKS O95271 1/20 0.31
▸ PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31161669 0.94 CNR1 (0.35) CNR1CRBNMEN1KMT2ADDB1
SCHEMBL31161548 0.87 CNR1 (0.41) CNR1CRBNMEN1KMT2ADDB1
SCHEMBL23123648 0.83 CNR1 (0.43) CNR1CRBNMEN1KMT2ADDB1
SCHEMBL31161308 0.83 CNR1 (0.43) CNR1CRBNMEN1KMT2ADDB1
SCHEMBL31161764 0.83 CNR1 (0.37) CNR1CRBNMEN1KMT2ADDB1
Trifluoroacetic Acid SCHEMBL30009088 0.81 CNR1 (0.40) CNR1CRBNMEN1KMT2ADDB1
SCHEMBL31161525 0.80 CNR1 (0.36) CNR1CRBNMEN1KMT2ADDB1
SCHEMBL27123605 0.80 SOS1 (0.43) CNR1CRBNMEN1KMT2ADDB1
SCHEMBL26099471 0.80 MEN1 (0.52) CRBNMEN1KMT2ADDB1PDK1
SCHEMBL31677220 0.78 MEN1 (0.41) CRBNMEN1KMT2ADDB1PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 CNR1 350/4885CRBN 91/4885MEN1 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback